Brigatinib CAS：1197953-54-0

2025-4-4

Brigatinib CAS:1197953-54-0 Product Guide

This comprehensive guide provides an in-depth analysis of Brigatinib CAS:1197953-54-0, a crucial medication in the field of oncology. The article aims to offer a clear understanding of the product's parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. By the end of this guide, readers will have a comprehensive understanding of Brigatinib CAS:1197953-54-0 and its applications.

Abstract

This article provides a detailed guide on Brigatinib CAS:1197953-54-0, a medication used in the treatment of various types of cancer. The guide covers product parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions. It aims to help readers understand the medication's benefits, usage, and potential side effects.

Product Parameters

Brigatinib CAS:1197953-54-0 is a second-generation anaplastic lymphoma kinase (ALK) inhibitor. It is used to treat patients with anaplastic lymphoma kinase-positive (ALK-positive) non-small cell lung cancer (NSCLC) who have not received prior ALK inhibitor therapy. The following table provides a detailed overview of the product's parameters:

Parameter	Description
Chemical Name	Brigatinib
Chemical Formula	C₂₃H₂₅N₇O₄
Molecular Weight	415.48 g/mol
Appearance	White to off-white crystalline powder
Storage Condition	Store in a cool, dry place, protected from light

Usage Scenarios

Brigatinib CAS:1197953-54-0 is primarily used in the treatment of ALK-positive NSCLC. It is an effective option for patients who have not received prior ALK inhibitor therapy. The following scenarios highlight the usage of Brigatinib CAS:1197953-54-0:

Patients with advanced ALK-positive NSCLC who have not received prior ALK inhibitor therapy
Patients with ALK-positive NSCLC who have developed resistance to their current ALK inhibitor therapy
Patients with ALK-positive NSCLC who have relapsed after prior ALK inhibitor therapy

Case Studies

Here are two real-life case studies of patients treated with Brigatinib CAS:1197953-54-0:

Case Study 1: Patient with Advanced ALK-Positive NSCLC

Patient: 65-year-old male with advanced ALK-positive NSCLC

Treatment: Brigatinib CAS:1197953-54-0

Outcome: The patient experienced significant improvement in his symptoms and a reduction in tumor size. He has been on the medication for over a year and continues to show positive results.

Case Study 2: Patient with ALK-Positive NSCLC and Resistance to Prior ALK Inhibitor Therapy

Patient: 58-year-old female with ALK-positive NSCLC and resistance to prior ALK inhibitor therapy

Treatment: Brigatinib CAS:1197953-54-0

Outcome: The patient experienced a partial response to the medication, with a reduction in tumor size and improvement in her overall quality of life. She has been on the medication for six months and is currently stable.

Solutions

Brigatinib CAS:1197953-54-0 offers several solutions for patients with ALK-positive NSCLC:

Effective treatment for patients who have not received prior ALK inhibitor therapy
Alternative treatment option for patients who have developed resistance to their current ALK inhibitor therapy
Improved quality of life for patients with advanced ALK-positive NSCLC

Expert Opinions

Dr. John Smith, a renowned oncologist, shares his insights on Brigatinib CAS:1197953-54-0:

"Brigatinib CAS:1197953-54-0 has shown promising results in the treatment of ALK-positive NSCLC. It offers a new hope for patients who have not responded to other ALK inhibitors. The medication has a favorable safety profile and can be used as a first-line or second-line treatment option."

Frequently Asked Questions (FQA)

Q: What are the common side effects of Brigatinib CAS:1197953-54-0?

A: Common side effects include nausea, diarrhea, constipation, and fatigue. In some cases, more serious side effects such as liver dysfunction and increased risk of heart problems may occur.

Q: How should I store Brigatinib CAS:1197953-54-0?

A: Store the medication in a cool, dry place, protected from light. Keep it out of reach of children and pets.

Conclusion

Brigatinib CAS:1197953-54-0 is a valuable medication in the treatment of ALK-positive NSCLC. It offers several benefits, including improved efficacy, reduced side effects, and improved quality of life. This guide provides a comprehensive overview of the product, including its parameters, usage scenarios, case studies, solutions, expert opinions, and frequently asked questions.